Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9495103 | 0.88 | SMN1; SMN2 (0.71) | ALDH1A1HPGDMAPTSMN1; SMN2CYP2C19 | |
| SCHEMBL3217401 | 0.84 | GAA (0.65) | ALDH1A1HPGDGAAMAPTSMN1; SMN2 | |
| SCHEMBL5142687 | 0.83 | GAA (0.77) | ALDH1A1HPGDGAAMAPTSMN1; SMN2 | |
| SCHEMBL11412031 | 0.82 | SMN1; SMN2 (0.64) | ALDH1A1HPGDMAPTSMN1; SMN2CYP2C19 | |
| SCHEMBL6579498 | 0.82 | MAPK1 (0.68) | ALDH1A1HPGDMAPTSMN1; SMN2CYP2C19 | |
| SCHEMBL5690831 | 0.81 | GAA (1.00) | ALDH1A1HPGDGAAEGFRMAPT | |
| SCHEMBL2502606 | 0.81 | NPC1 (0.76) | ALDH1A1HPGDGAAMAPTSMN1; SMN2 | |
| SCHEMBL11302253 | 0.81 | SMN1; SMN2 (0.62) | ALDH1A1HPGDMAPTSMN1; SMN2CYP2C19 | |
| SCHEMBL11680494 | 0.81 | SMN1; SMN2 (0.62) | ALDH1A1HPGDMAPTSMN1; SMN2CYP2C19 | |
| SCHEMBL28429030 | 0.80 | ALDH1A1 (0.72) | ALDH1A1HPGDGAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643308-B1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2021-05-19 | — | — | EP | disclosed |
| EP-3643308-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-04-29 | — | — | EP | disclosed |
| WO-2016000615-A1 | HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-01-07 | — | — | WO | disclosed |
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | ALDH1A1 2041/4885HPGD 1677/4885GAA 3465/4885 |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | ALDH1A1 2041/4885HPGD 1677/4885GAA 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.